The work of Farlow et al. [13] incorporated non-neoplastic lung diseases and inflammatory conditions for comparison against NSCLC and defined a six-marker panel using random forest and CART algorithms, comprised by TNF-α, CYFRA, Interleukin 1ra, Matrix Metalloproteinase-2, Monocyte chemotactic protein 1 and sE-selectin. This evidence concerns the gene CCL2 and lung disorder.